Jacobs Levy Equity Management Inc. Buys 1,226,377 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Jacobs Levy Equity Management Inc. lifted its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 40.8% during the first quarter, Holdings Channel.com reports. The firm owned 4,235,580 shares of the biotechnology company’s stock after acquiring an additional 1,226,377 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Ironwood Pharmaceuticals were worth $36,892,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC boosted its position in shares of Ironwood Pharmaceuticals by 61.4% during the 4th quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 822 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in Ironwood Pharmaceuticals by 331.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,900 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Ironwood Pharmaceuticals by 152.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,645 shares in the last quarter. SG Americas Securities LLC bought a new position in Ironwood Pharmaceuticals in the 1st quarter valued at about $91,000. Finally, EntryPoint Capital LLC lifted its position in Ironwood Pharmaceuticals by 517.4% in the 1st quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 8,874 shares in the last quarter.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Catherine Moukheibir sold 44,426 shares of the firm’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $6.36, for a total value of $282,549.36. Following the completion of the transaction, the director now directly owns 84,207 shares of the company’s stock, valued at approximately $535,556.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Ironwood Pharmaceuticals news, Director Julie Mchugh sold 22,766 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $6.29, for a total value of $143,198.14. Following the completion of the transaction, the director now directly owns 139,528 shares of the company’s stock, valued at approximately $877,631.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Catherine Moukheibir sold 44,426 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $6.36, for a total transaction of $282,549.36. Following the sale, the director now directly owns 84,207 shares of the company’s stock, valued at $535,556.52. The disclosure for this sale can be found here. Insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Stock Performance

IRWD remained flat at $6.94 on Tuesday. 1,341,510 shares of the company traded hands, compared to its average volume of 3,498,404. The stock’s 50 day simple moving average is $6.36 and its 200 day simple moving average is $8.96. Ironwood Pharmaceuticals, Inc. has a 52 week low of $5.47 and a 52 week high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.18 by ($0.20). The business had revenue of $74.90 million during the quarter, compared to the consensus estimate of $105.75 million. Ironwood Pharmaceuticals had a negative return on equity of 28.45% and a negative net margin of 254.41%. The firm’s quarterly revenue was down 28.0% on a year-over-year basis. During the same period last year, the business posted $0.25 earnings per share. Research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on IRWD. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Craig Hallum decreased their price objective on shares of Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $18.40.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.